Haploidentical Hematopoietic Stem Cell Transplantation
8
3
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
Blood Virome After Haploidentical Hematopoietic Stem Cell Transplantation, a Pilot Study
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation
Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation
Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents